Thermo Fisher Scientific is opening a new facility in Hangzhou, China, as part of its global effort to help companies provide therapies to patients more quickly. The site can address the needs of organisations in China, as well as those outside that country, for biologics and steriles development and manufacturing capabilities in the Asia Pacific region.

The 80,000-square-meter current Good Manufacturing Practices (cGMP) facility will offer integrated clinical and commercial drug substance and drug product capabilities, including process development, cell line development, biologics drug substance manufacturing and sterile fill-finish.

Eventually, it will also feature commercial packaging and labeling capabilities. Advanced technologies in the facility include Thermo Fisher 2,000-liter HyPerforma Single-Use Bioreactors and associated Single-Use equipment and, in the future, bioreactor capacity up to 5,000 liters through Thermo Scientific DynaDrive technology.

The site incorporates stringent quality control processes that meet or exceed regulatory guidelines established by the China National Medical Products Administration (NMPA), the US Food and Drug Administration, and authorities in Europe and elsewhere.

With this facility and Thermo Fisher’s current capabilities in clinical packaging and logistics, the company can now offer a seamless end-to-end solution from molecule development through the accelerated delivery of critical medicines to patients.